Epidermal growth factor receptor (EGFR) in the era of Precision Medicine: The tale of a perfect example of targeted therapy. A review
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier B.V.
Abstract
Epidermal growth factor receptor has been under the lights for the past few years as a perfect and typical example of a success story of targeted therapy. In the era of Precision Medicine, such modalities of treatment are highly implicated in the adequate choice of therapy for a wide variety of oncological diseases. This review article is about the different aspects of detection, application, and analysis of the epidermal growth factor receptor genetic mutations that constitute a key element in the initiation of targeted therapy. © 2016 Elsevier B.V.
Description
Keywords
Egfr, Medicine, Precision, Review, Anaplastic lymphoma kinase, Ceritinib, Cetuximab, Crizotinib, Dacomitinib, Epidermal growth factor receptor, Erlotinib, Gefitinib, K ras protein, Panitumumab, Platelet derived growth factor, Vasculotropin, Cancer prognosis, Clinical trial (topic), Colorectal carcinoma, Dna sequence, Gene mutation, Glioblastoma, Head and neck carcinoma, High performance liquid chromatography, Human, Immunohistochemistry, Lung cancer, Molecularly targeted therapy, Next generation sequencing, Personalized medicine, Priority journal, Progression free survival, Pyrosequencing, Quality of life, Reverse transcription polymerase chain reaction, Sensitivity and specificity, Treatment outcome, Treatment response